Ensysce Biosciences Announces The Co May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To May 13, 2024 In Order To Demonstrate Compliance With The Equity Requirement In Listing Rule 5550(b)(1)
Portfolio Pulse from Benzinga Newsdesk
Ensysce Biosciences, Inc. (ENSC) has received an extension until May 13, 2024, to continue its listing on The Nasdaq Capital Market tier. This extension allows the company to demonstrate compliance with the equity requirement in Listing Rule 5550(b)(1).
February 27, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ensysce Biosciences, Inc. has been granted an extension to demonstrate compliance with Nasdaq's equity requirement, allowing it to continue its listing on The Nasdaq Capital Market tier until May 13, 2024.
The extension granted to Ensysce Biosciences by Nasdaq is a positive development, indicating the company has more time to meet the equity requirements for listing. This news is likely to be viewed positively by investors as it reduces the immediate risk of delisting, potentially leading to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100